Cargando…
Postpartum breast cancer has a distinct molecular profile that predicts poor outcomes
Young women’s breast cancer (YWBC) has poor prognosis and known interactions with parity. Women diagnosed within 5–10 years of childbirth, defined as postpartum breast cancer (PPBC), have poorer prognosis compared to age, stage, and biologic subtype-matched nulliparous patients. Genomic differences...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8566602/ https://www.ncbi.nlm.nih.gov/pubmed/34732713 http://dx.doi.org/10.1038/s41467-021-26505-3 |
_version_ | 1784594051442409472 |
---|---|
author | Jindal, Sonali Pennock, Nathan D. Sun, Duanchen Horton, Wesley Ozaki, Michelle K. Narasimhan, Jayasri Bartlett, Alexandra Q. Weinmann, Sheila Goss, Paul E. Borges, Virginia F. Xia, Zheng Schedin, Pepper |
author_facet | Jindal, Sonali Pennock, Nathan D. Sun, Duanchen Horton, Wesley Ozaki, Michelle K. Narasimhan, Jayasri Bartlett, Alexandra Q. Weinmann, Sheila Goss, Paul E. Borges, Virginia F. Xia, Zheng Schedin, Pepper |
author_sort | Jindal, Sonali |
collection | PubMed |
description | Young women’s breast cancer (YWBC) has poor prognosis and known interactions with parity. Women diagnosed within 5–10 years of childbirth, defined as postpartum breast cancer (PPBC), have poorer prognosis compared to age, stage, and biologic subtype-matched nulliparous patients. Genomic differences that explain this poor prognosis remain unknown. In this study, using RNA expression data from clinically matched estrogen receptor positive (ER+) cases (n = 16), we observe that ER+ YWBC can be differentiated based on a postpartum or nulliparous diagnosis. The gene expression signatures of PPBC are consistent with increased cell cycle, T-cell activation and reduced estrogen receptor and TP53 signaling. When applied to a large YWBC cohort, these signatures for ER+ PPBC associate with significantly reduced 15-year survival rates in high compared to low expressing cases. Cumulatively these results provide evidence that PPBC is a unique entity within YWBC with poor prognostic phenotypes. |
format | Online Article Text |
id | pubmed-8566602 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-85666022021-11-15 Postpartum breast cancer has a distinct molecular profile that predicts poor outcomes Jindal, Sonali Pennock, Nathan D. Sun, Duanchen Horton, Wesley Ozaki, Michelle K. Narasimhan, Jayasri Bartlett, Alexandra Q. Weinmann, Sheila Goss, Paul E. Borges, Virginia F. Xia, Zheng Schedin, Pepper Nat Commun Article Young women’s breast cancer (YWBC) has poor prognosis and known interactions with parity. Women diagnosed within 5–10 years of childbirth, defined as postpartum breast cancer (PPBC), have poorer prognosis compared to age, stage, and biologic subtype-matched nulliparous patients. Genomic differences that explain this poor prognosis remain unknown. In this study, using RNA expression data from clinically matched estrogen receptor positive (ER+) cases (n = 16), we observe that ER+ YWBC can be differentiated based on a postpartum or nulliparous diagnosis. The gene expression signatures of PPBC are consistent with increased cell cycle, T-cell activation and reduced estrogen receptor and TP53 signaling. When applied to a large YWBC cohort, these signatures for ER+ PPBC associate with significantly reduced 15-year survival rates in high compared to low expressing cases. Cumulatively these results provide evidence that PPBC is a unique entity within YWBC with poor prognostic phenotypes. Nature Publishing Group UK 2021-11-03 /pmc/articles/PMC8566602/ /pubmed/34732713 http://dx.doi.org/10.1038/s41467-021-26505-3 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Article Jindal, Sonali Pennock, Nathan D. Sun, Duanchen Horton, Wesley Ozaki, Michelle K. Narasimhan, Jayasri Bartlett, Alexandra Q. Weinmann, Sheila Goss, Paul E. Borges, Virginia F. Xia, Zheng Schedin, Pepper Postpartum breast cancer has a distinct molecular profile that predicts poor outcomes |
title | Postpartum breast cancer has a distinct molecular profile that predicts poor outcomes |
title_full | Postpartum breast cancer has a distinct molecular profile that predicts poor outcomes |
title_fullStr | Postpartum breast cancer has a distinct molecular profile that predicts poor outcomes |
title_full_unstemmed | Postpartum breast cancer has a distinct molecular profile that predicts poor outcomes |
title_short | Postpartum breast cancer has a distinct molecular profile that predicts poor outcomes |
title_sort | postpartum breast cancer has a distinct molecular profile that predicts poor outcomes |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8566602/ https://www.ncbi.nlm.nih.gov/pubmed/34732713 http://dx.doi.org/10.1038/s41467-021-26505-3 |
work_keys_str_mv | AT jindalsonali postpartumbreastcancerhasadistinctmolecularprofilethatpredictspooroutcomes AT pennocknathand postpartumbreastcancerhasadistinctmolecularprofilethatpredictspooroutcomes AT sunduanchen postpartumbreastcancerhasadistinctmolecularprofilethatpredictspooroutcomes AT hortonwesley postpartumbreastcancerhasadistinctmolecularprofilethatpredictspooroutcomes AT ozakimichellek postpartumbreastcancerhasadistinctmolecularprofilethatpredictspooroutcomes AT narasimhanjayasri postpartumbreastcancerhasadistinctmolecularprofilethatpredictspooroutcomes AT bartlettalexandraq postpartumbreastcancerhasadistinctmolecularprofilethatpredictspooroutcomes AT weinmannsheila postpartumbreastcancerhasadistinctmolecularprofilethatpredictspooroutcomes AT gosspaule postpartumbreastcancerhasadistinctmolecularprofilethatpredictspooroutcomes AT borgesvirginiaf postpartumbreastcancerhasadistinctmolecularprofilethatpredictspooroutcomes AT xiazheng postpartumbreastcancerhasadistinctmolecularprofilethatpredictspooroutcomes AT schedinpepper postpartumbreastcancerhasadistinctmolecularprofilethatpredictspooroutcomes |